Literature DB >> 27075078

Cocktails for cancer with a measure of immunotherapy.

Heidi Ledford.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27075078     DOI: 10.1038/532162a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

1.  Hepatotoxicity with combination of vemurafenib and ipilimumab.

Authors:  Antoni Ribas; F Stephen Hodi; Margaret Callahan; Cyril Konto; Jedd Wolchok
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

4.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

5.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

  5 in total
  19 in total

Review 1.  Resistance to immunotherapy: clouds in a bright sky.

Authors:  Gérard Milano
Journal:  Invest New Drugs       Date:  2017-04-12       Impact factor: 3.850

Review 2.  Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors:  Yu Yu; Jiuwei Cui
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

Review 3.  Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health.

Authors:  Feixiong Cheng; Han Liang; Atul J Butte; Charis Eng; Ruth Nussinov
Journal:  Pharmacol Rev       Date:  2018-12-13       Impact factor: 25.468

4.  Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome.

Authors:  Tomohiro Matsumoto; Koji Fukuda; Taichi Yoshida; Kazuhiro Shimazu; Daiki Taguchi; Hanae Shinozaki; Katsuhito Seki; Takayuki Yamanaka; Mako Ootaka; Hiroshi Nanjyo; Hiroyuki Watanabe; Hiroyuki Shibata
Journal:  Int Cancer Conf J       Date:  2021-11-22

5.  cSurvival: a web resource for biomarker interactions in cancer outcomes and in cell lines.

Authors:  Xuanjin Cheng; Yongxing Liu; Jiahe Wang; Yujie Chen; Andrew Gordon Robertson; Xuekui Zhang; Steven J M Jones; Stefan Taubert
Journal:  Brief Bioinform       Date:  2022-05-13       Impact factor: 13.994

6.  Mitochondrial autophagosomes as a mechanism of drug resistance in breast carcinoma.

Authors:  Ayman N Abunimer; Heba Mohammed; Katherine L Cook; David R Soto-Pantoja; Maria Mercedes Campos; Mones S Abu-Asab
Journal:  Ultrastruct Pathol       Date:  2018-02-08       Impact factor: 1.094

7.  The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody.

Authors:  Sheena N Smith; Rajib Schubert; Branko Simic; Dominik Brücher; Markus Schmid; Niels Kirk; Patrick C Freitag; Viviana Gradinaru; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 11.205

8.  Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.

Authors:  Sarah L Hulin-Curtis; James A Davies; Rachel Jones; Emma Hudson; Louise Hanna; John D Chester; Alan L Parker
Journal:  Oncotarget       Date:  2018-05-29

9.  Guidelines for Reopening a Nation in a SARS-CoV-2 Pandemic: A Path Forward.

Authors:  Terrance L Baker; Jack V Greiner
Journal:  Medicina (Kaunas)       Date:  2021-05-14       Impact factor: 2.430

Review 10.  Cardiotoxicity of Anticancer Therapeutics.

Authors:  Jerry Dong; Hong Chen
Journal:  Front Cardiovasc Med       Date:  2018-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.